Prayag Parikshit Shirish, Patwardhan Sampada Ajeet, Ajapuje Preeti Shankarrao, Melinkeri Sameer, Gadhikar Harshal, Palnitkar Sachin, Simbasivam Ramya, Joshi Rasika Saheel, Baheti Abhijit, Sheth Urmi Sitanshu, Prayag Amrita Parikshit
Department of Infectious Diseases, Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India.
Department of Microbiology, Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India.
Indian J Crit Care Med. 2024 Feb;28(2):106-110. doi: 10.5005/jp-journals-10071-24607.
Fecal microbiota transplantation (FMT) is an emerging option for recurrent or refractory -associated diarrhea (CDAD). We describe a single-center experience of FMT in hematopoietic stem cell transplant (HSCT) recipients with CDAD in India.
A prospective observational study of HSCT recipients with CDAD who received FMT in our center.
A total of 13 patients were included. All the patients were allogenic HSCT recipients; FMT was performed in seven patients due to refractory CDAD, in five patients due to the presence of both CDAD and graft vs host disease (GVHD), and in 1 patient due to recurrent CDAD. The approach to FMT was colonoscopic in 10 (77%) patients. Only one patient reported bacteremia and one patient had candidemia, both of which were unrelated to FMT. Of the 10 patients who had complete resolution of CDAD, only one patient presented with a recurrence of CDAD within 8 weeks post-FMT.
This is the first study from India using FMT as a therapeutic modality for CDAD in the setting of HSCT. Here we demonstrate that FMT in India is an effective option, especially when patients have refractory CDAD, recurrent CDAD, or both GVHD and CDAD. Further studies should explore the efficacy and feasibility of FMT in India.
Prayag PS, Patwardhan SA, Ajapuje PS, Melinkeri S, Gadhikar H, Palnitkar S, . Fecal Microbiota Transplantation for -associated Diarrhea in Hematopoietic Stem Cell Transplant Recipients: A Single-center Experience from a Tertiary Center in India. Indian J Crit Care Med 2024;28(2):106-110.
粪便微生物群移植（FMT）是复发性或难治性艰难梭菌相关性腹泻（CDAD）的一种新兴治疗选择。我们描述了印度一家单中心对造血干细胞移植（HSCT）受者合并CDAD进行FMT的经验。
对在我们中心接受FMT的HSCT合并CDAD受者进行前瞻性观察研究。
共纳入13例患者。所有患者均为异基因HSCT受者；7例患者因难治性CDAD接受FMT，5例患者因同时存在CDAD和移植物抗宿主病（GVHD）接受FMT，1例患者因复发性CDAD接受FMT。10例（77%）患者采用结肠镜下FMT方法。仅1例患者报告发生菌血症，1例患者发生念珠菌血症，两者均与FMT无关。在10例CDAD完全缓解的患者中，仅1例在FMT后8周内出现CDAD复发。
这是印度第一项将FMT作为HSCT背景下CDAD治疗方式的研究。我们在此证明，在印度FMT是一种有效的选择，尤其是当患者患有难治性CDAD、复发性CDAD或同时患有GVHD和CDAD时。进一步的研究应探索FMT在印度的疗效和可行性。
Prayag PS, Patwardhan SA, Ajapuje PS, Melinkeri S, Gadhikar H, Palnitkar S, 。造血干细胞移植受者艰难梭菌相关性腹泻的粪便微生物群移植：印度一家三级中心的单中心经验。《印度重症监护医学杂志》2024；28(2):106 - 110 。
